Child Categories
Food & Drug Law
-
The FDA Declares Levonorgestrel a Nonabortifacient—A 50-Year Saga Takes a Decisive Turn
December 4, 2024
Eli Y. Adashi, I. Glenn Cohen & Allen J. Wilcox, The FDA Declares Levonorgestrel a Nonabortifacient—A 50-Year Saga Takes a Decisive Turn, 8 JAMA Health…
-
Eli Y. Adashi, Daniel P. O’Mahony & I. Glenn Cohen, The Inflation Reduction Act: Recasting the Medicare Prescription Drug Plans, Am. J. Preventative Med. (2023).
-
Eli Y. Adashi & I. Glenn Cohen, The FDA Initiative to Assure Racial and Ethnic Diversity in Clinical Trials, 36 J. Am. Bd. Fam. Med.
-
Integrity of SARS-CoV-2 Laboratory-Developed Tests—Reply
December 4, 2024
Eli Y. Adashi & I. Glenn Cohen, Integrity of SARS-CoV-2 Laboratory-Developed Tests—Reply, 328 JAMA 478 (2022).
-
Mason Marks & I. Glenn Cohen, Patents on Psychedelics: The Next Legal Battlefront of Drug Development, 135 Harv. L. Rev. F. (2022).
-
Kerry Lynn Macintosh, I. Glenn Cohen, Jacob. S. Sherkow & Eli Y. Adashi, Gene Editing Sperm and Eggs for Use in Clinical Trials – The…
-
Every Pill You Take
December 4, 2024
I. Glenn Cohen & Alex Pearlman, Every Pill You Take, New Scientist, Sept. 29, 2018, at 22.
-
Influence, Integrity, and the FDA: An Ethical Framework
December 4, 2024
Spencer Phillips Hey, I. Glenn Cohen, Eli Y. Adashi & Aaron S. Kesselheim, Influence, Integrity, and the FDA: An Ethical Framework, 357 Science 876 (2017).
-
A New Regulatory Function for E-Prescriptions: Linking the FDA to Physicians and Patient Records
December 4, 2024
Andrew English, David Rosenberg & Huaou Yan, A New Regulatory Function for E-Prescriptions: Linking the FDA to Physicians and Patient Records (Harv. L. Sch. Pub.
-
I. Glenn Cohen & Nicholas Bagley, Private Rights and the Public Interest in Drug and Medical Device Litigation, 180 JAMA Internal Med. 299 (2019).
-
Ethical and Legal Issues of Ingestible Electronic Sensors
December 4, 2024
Sara Gerke, Timo Minssen, Helen Yu & I. Glenn Cohen, Ethical and Legal Issues of Ingestible Electronic Sensors, 2 Nature Electronics 329 (2019).
-
Regulation of Stem Cell Therapy Travel
December 4, 2024
I. Glenn Cohen & Shelly Simana, Regulation of Stem Cell Therapy Travel, 4 Current Stem Cell Rep. 220 (2018).
-
Mutual Pharmaceutical Co. v. Bartlett and Its Implications
December 2, 2024
Brian Wolfman & Anne King, Mutual Pharmaceutical Co. v. Bartlett and Its Implications, 82 U.S.L.W., no. 17, at 1 (Nov. 5, 2013).
-
State Legal Initiatives to Restrict and Protect Mifepristone Access
November 15, 2024
Eli Y. Adashi, Daniel P. O’Mahony & I. Glenn Cohen, State Legal Initiatives to Restrict and Protect Mifepristone Access, 107 R.I. Med. J. 44 (2024).
-
Random Drug Testing of Physicians: A Question of Safety
July 30, 2024
Jeffrey A. Julian, Eli Y. Adashi & I. Glenn Cohen, Random Drug Testing of Physicians: A Question of Safety, 25 DePaul J. Health Care L.
-
If We Are What We Eat, We Don’t Know Who We Are
April 13, 2024
Jacob E. Gersen, If We Are What We Eat, We Don’t Know Who We Are, N.Y. Times, July 7, 2023 (reviewing Chris van Tulleken, Ultra-Processed…
-
William W. Fisher, Ruth Okediji & Padmashree Gehl Sampath, Fostering Production of Pharmaceutical Products in Developing Countries, 43 Mich. J. Int’l L. (2022).
-
An Antitrust Framework for False Advertising
January 25, 2024
Michael A. Carrier & Rebecca Tushnet, An Antitrust Framework for False Advertising, 106 Iowa L. Rev. 1841 (2021).
-
Advertising & Marketing Law Cases & Materials, 4th ed., vol. 2
January 25, 2024
Eric Goldman & Rebecca Tushnet, 2 Advertising & Marketing Law Cases & Materials(4th ed. 2019).
-
COOL Story: Country of Origin Labeling and the First Amendment
January 25, 2024
Rebecca Tushnet, COOL Story: Country of Origin Labeling and the First Amendment, 70 Food & Drug L.J. 25 (2015).
-
A History of Medical Innovation That Doesn’t Ignore the Side Effects
January 25, 2024
Cass R. Sunstein, A History of Medical Innovation That Doesn’t Ignore the Side Effects, N.Y. Times, Oct. 25, 2021.